Novartis shares drop after drug trial fails
Novartis shares fell after its cholesterol drug pelacarsen missed its primary goal in a late-stage study. The setback increases pressure on upcoming pipeline data for the Swiss drugmaker.
Xurve View
Insights:
Xurve View
NOVARTIS AG-REG shares fell 3.3% on Monday morning after its experimental cholesterol drug failed a key clinical trial. The setback casts doubt on a therapeutic approach targeting Lp(a) proteins. The failure increases pressure on upcoming pipeline data for the Switzerland-based drugmaker.
